Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: This patient presents with a...

Question asked:

Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: This patient presents with a highly challenging case: AR-positive, HER2-negative salivary duct carcinoma (SDC) with extensive nodal involvement (16/25 nodes, N3b) and confirmed bone metastases. The standard NCCN approach for advanced SDC emphasizes platinum-based chemotherapy as first-line systemic therapy, followed by consideration of androgen deprivation therapy (ADT) given strong AR positivity. However, this patient has already progressed through multiple lines including chemotherapy and is currently on Lupron monotherapy with documented radiographic progression in bone metastases. Recommendation: Tumor board consensus: (1) Urgent palliative radiation to left hip for fracture prevention, (2) Continue Lupron to maintain castrate testosterone levels, (3) Add abiraterone acetate + prednisone as intensified androgen blockade (next-generation AR-targeted therapy), and (4) Simultaneously pursue clinical trial screening for SDC-specific protocols or genomically-matched trials targeting CDKN2/NF1 pathways. If abiraterone fails or is not tolerated, return to platinum-doublet chemotherapy or consider off-label trastuzumab given borderline HER2 2+ status with reflex FISH testing. Tumor Board: Cutting Edge: This AR-positive, HER2-negative salivary duct carcinoma with extensive nodal involvement (16/25 nodes, ENE+) and now bone-metastatic disease represents a precision medicine opportunity. The CDKN2A and NF1 pathogenic variants, combined with AR-positivity and progression on Lupron monotherapy, suggest combination androgen blockade plus targeted therapy addressing cell cycle dysregulation may offer superior disease control compared to continued single-agent ADT. Recommendation: Recommend: (1) Reflex HER2 FISH testing on archived tissue - if amplified, pivot to HER2-directed therapy (trastuzumab + pertuzumab + taxane or T-DM1); (2) If HER2-negative confirmed, intensify androgen blockade with abiraterone/prednisone + continued Lupron, adding palbociclib 125mg (CDK4/6i) given CDKN2A loss; (3) Orthopedic consultation for impending left hip fracture (prophylactic fixation) + Ra-223 or denosumab for skeletal-related events; (4) Enroll in precision medicine trial if available, particularly platforms addressing NF1/CDKN2A co-alterations. This combination approach addresses the AR-driven biology while exploiting cell cycle vulnerabilities, with HER2 status determining primary therapeutic backbone. Tumor Board: Whole Person: This patient with AR-positive, HER2-negative salivary duct carcinoma and extensive bone metastases requires aggressive supportive care to optimize treatment tolerance and quality of life. Given the history of treatment discontinuation due to depression and sleep problems, plus ongoing hormone therapy (Lupron) with progressive bone disease, the priority is managing bone health, psychological symptoms, and treatment-related side effects to maintain therapeutic adherence. Recommendation: Implement a comprehensive supportive care plan: (1) Bone-modifying therapy + calcium/vitamin D + supervised exercise program emphasizing resistance training and fall prevention; (2) Psychiatric consultation for depression/sleep management with CBT-I and appropriate pharmacotherapy; (3) Oncology nutrition consultation for high-protein, anti-inflammatory diet; (4) Palliative care integration NOW (not end-of-life) to optimize symptom management and treatment tolerance. This multimodal approach addresses the specific reasons for prior treatment failure (depression, sleep) while protecting against the primary risk (pathologic fracture) and supporting continued androgen deprivation therapy adherence. Synthesize these perspectives. Respond in this exact JSON format: { "synthesis": "A 2-3 sentence synthesis of the key takeaways for the patient", "consensus": ["Point where all three agree", "Another point of agreement"], "divergence": ["Point where they disagree", "Another area of disagreement"] } Focus on actionable insights for the patient's next doctor conversation.